Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN301 An Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-cell Non-Hodgkin's Lymphoma

Next Previous
Trial Profile

A Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN301 An Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-cell Non-Hodgkin's Lymphoma

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STRO 001 (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioNova Pharmaceuticals

Most Recent Events

  • 20 Feb 2024 Status changed from recruiting to discontinued.
  • 23 Mar 2023 Status changed from not yet recruiting to recruiting.
  • 15 Feb 2023 According to a BioNova Pharmaceuticals media release, first patient in this trial has been dosed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top